Mounjaro (Tirzepatide)

Tirzepatide is a dual agonist of the GIP and GLP‑1 receptors. By activating both incretin pathways, it increases insulin secretion in response to glucose, suppresses glucagon release, slows gastric emptying, and reduces appetite, resulting in improved glycaemic control and weight loss.

The dosing regimen for tirzepatide is individualized by the prescribing healthcare professional. The prescriber determines the starting dose, titration schedule, and maintenance dose based on the patient’s clinical condition, response, and tolerability, following the product’s prescribing information.

The safety of tirzepatide during pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Mounjaro. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and necessary import documentation.

Compared with single‑agonist GLP‑1 receptor agonists, tirzepatide’s dual GIP/GLP‑1 activity provides greater reductions in HbA1c and body weight in clinical studies. However, the safety profile, dosing frequency, and cost may differ, and the choice of therapy should be individualized based on patient characteristics and treatment goals.

Mounjaro should be stored in a refrigerator at 2 °C to 8 °C (36 °F to 46 °F). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If a temporary temperature excursion occurs, discard the product according to the supplier’s guidelines.

Mounjaro is supplied as a solution for injection and is administered subcutaneously, typically in the abdomen, thigh, or upper arm. The injection is performed by a trained healthcare professional or by the patient after appropriate instruction, following the dosing schedule prescribed by the clinician.

The most serious risks associated with tirzepatide include pancreatitis, severe allergic reactions such as anaphylaxis, and potential thyroid C‑cell tumors observed in animal studies. Patients should be educated to seek immediate medical attention for persistent abdominal pain, signs of hypersensitivity, or neck swelling.

Mounjaro is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and it should not be used in patients with known hypersensitivity to tirzepatide or any of the excipients. Caution is also advised in those with severe renal impairment.